Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ERCC8
REST API REST API
Homo sapiens
ERCC8 is differentially expressed in 266 experiments: 119 organism parts: lung, bone marrow, ... (117 more);, 179 disease states: normal, breast carcinoma, ... (177 more);, 87 cell types 345 cell lines 33 compound treatments and 78 other conditions.
Synonyms CSA, CKN1
Orthologs ERCC8 (Gallus gallus)   Ercc8 (Mus musculus)   Q4H3S8_CIOIN (Ciona intestinalis)   ercc8 (Danio rerio)   RAD28 (Saccharomyces cerevisiae)   ERCC8_BOVIN (Bos taurus)   Ercc8 (Rattus norvegicus)   ercc8 (Xenopus laevis)   ENSXETG00000031181 (Xenopus laevis)   ERCC8 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term response to UV, response to oxidative stress, nucleotide-excision repair, proteasomal ubiquitin-dependent protein catabolic process, protein binding, protein autoubiquitination, DNA repair, protein complex, nuclear matrix, soluble fraction, nucleus, protein polyubiquitination, ubiquitin-protein ligase activity, nucleoplasm, response to DNA damage stimulus, response to X-ray, transcription-coupled nucleotide-excision repair, nucleotide-excision repair complex, positive regulation of DNA repair, Cul4A-RING ubiquitin ligase complex, protein complex binding
InterPro Term WD40_repeat_dom, WD40_repeat, WD40_repeat_2, G-protein_beta_WD-40_rep, WD40_repeat_subgr
UniProt Accession Q13216, C9JNT2, B4E383, B4DGZ9, B3KPW7
Gene-Disease Assocation COCKAYNE SYNDROME, TYPE A; CSA
Search EB-eye ENSG00000049167
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (38 experiments)

Factor Value U/D Experiments
SW480
3
E-GEOD-18005, E-MEXP-1014, E-MTAB-37
SNU16
2
E-MTAB-37, E-GEOD-15460
HT1080
2
E-GEOD-20089, E-MTAB-37
A549
2
E-GEOD-6013, E-GEOD-3202
BT-474
2
E-GEOD-5823, E-GEOD-3529
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
339 more value(s).


Cell type

studied in E-MEXP-1242, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-13909, ... (43 experiments)

Factor Value U/D Experiments
CD34+
2
E-TABM-145, E-AFMX-5
peripheral blood mononuclear cell
1
E-GEOD-3026
stromal cell
1
E-GEOD-1460
leydig cell
1
E-MTAB-25
neuroblastoma cell
1
E-MEXP-669
primary T lymphocytes
1
E-GEOD-13909
81 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-2280, E-GEOD-16363, E-MTAB-62, ... (51 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-GEOD-4290, E-MTAB-62, E-MTAB-37
adenocarcinoma
2
E-MTAB-37, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
control
2
E-GEOD-21912, E-GEOD-8121
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
breast carcinoma
1
2
E-MTAB-37, E-TABM-276, E-MEXP-882
173 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-6907, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (22 experiments)

Factor Value U/D Experiments
none
2
6
E-GEOD-5824, E-TABM-868, E-GEOD-412, E-GEOD-7307, E-TABM-782, ... (8 experiments)
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
glutamine
1
E-MEXP-1335
M-CSF
1
1
E-GEOD-5099
actinomycin D
1
E-GEOD-6400
estradiol
1
E-GEOD-20081
27 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
39
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-4619, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, E-MEXP-2283, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MEXP-2340 ... (5 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-22593, E-TABM-321, E-TABM-868, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-7011, E-MEXP-2657, E-TABM-127, E-MEXP-1446, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-TABM-15, ... (29 experiments)

Infection
studied in E-MEXP-1274, E-MEXP-561, E-GEOD-17400, E-GEOD-6802

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-MEXP-548, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246, E-GEOD-19815, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541, E-GEOD-6532

Tumor size
studied in E-GEOD-8167

Vehicle
studied in E-GEOD-5258

Processing time: 0.345 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM